logo
Hepato Burn Reviews and Complaints (CRITICAL INVESTIGATION) With Hepato Burn Speed up Calorie Burning

Hepato Burn Reviews and Complaints (CRITICAL INVESTIGATION) With Hepato Burn Speed up Calorie Burning

Business Upturn11-05-2025

AURORA, Colo., May 10, 2025 (GLOBE NEWSWIRE) — In today's fast-paced world, health and wellness have become more important than ever. With the rising awareness of how our body's metabolism plays a vital role in maintaining overall health, there has been an increasing demand for supplements that can support metabolism, weight management, and liver health. One such product that has garnered attention in the health community is Hepato Burn – a cutting-edge metabolism supplement designed to promote a healthy liver and help you achieve your weight loss goals.
Are you looking for a weight loss supplement that can provide instant results? Look no further than Hepato Burn! These pills work by encouraging your body to burn more calories and fat, which in turn helps you lose weight. In this blog, we'll go over the product overview, features, how it works, and possible side effects.
Buy Now and Experience the Power of Hepato Burn for Enhanced Metabolism and Liver Health
Introduction: What is Hepato Burn?
Hepato Burn is an advanced supplement formulated to support healthy liver function, improve metabolism, and assist in the body's natural fat-burning processes. This supplement is a unique blend of scientifically-backed ingredients designed to help individuals struggling with weight management, sluggish metabolism, or liver health issues.
Hepato Burn works by targeting the liver, the body's primary detoxifying organ, which plays a crucial role in fat metabolism and detoxification. By enhancing liver function, the supplement helps to break down fats more effectively, leading to better weight management and overall well-being.
NOTE – Hepato Burn and BurnJaro are both effective supplements designed to support weight loss and enhance overall health, but they focus on different aspects of wellness and also read BurnJaro Reviews and Complaints.
The Science Behind Hepato Burn
The liver is responsible for various functions, including detoxification, digestion, and metabolism. When the liver becomes overburdened, often due to poor diet, alcohol consumption, or environmental toxins, its efficiency in processing fats and toxins decreases, leading to slow metabolism, fat accumulation, and even liver diseases.
Hepato Burn aims to address these concerns by optimizing liver function, helping the body naturally eliminate toxins, and enhancing metabolic activity. This promotes effective fat breakdown, better energy levels, and healthier body composition.
Ingredients of Hepato Burn
Hepato Burn is formulated with a combination of natural ingredients, each chosen for its ability to support metabolism, liver health, and weight loss. Let's take a closer look at some of the key components that make this supplement effective: Milk Thistle (Silymarin)
Milk Thistle is one of the most powerful liver-supporting herbs. It contains silymarin, a potent antioxidant that helps protect liver cells from damage, reduces inflammation, and supports liver detoxification. Studies have shown that milk thistle can help improve liver function, making it a key ingredient in Hepato Burn. Turmeric Extract (Curcumin)
Curcumin, the active compound in turmeric, is known for its anti-inflammatory and antioxidant properties. It not only helps reduce inflammation in the liver but also promotes fat metabolism and helps in the removal of toxins from the body. Curcumin has been shown to enhance liver health and support healthy metabolic functions. Cinnamon Extract
Cinnamon has long been known for its ability to regulate blood sugar levels, which is vital for maintaining a healthy metabolism. It also aids in fat burning by boosting the body's ability to burn calories. Cinnamon supports insulin sensitivity, which plays a crucial role in fat storage and metabolism. Green Tea Extract
Green Tea Extract is rich in antioxidants, specifically catechins, which are known to support fat loss by increasing metabolic rate. It promotes thermogenesis, which increases the body's ability to burn fat. Green tea extract is also known for its liver detoxification properties, making it an excellent addition to Hepato Burn's formula. Ginger Root Extract
Ginger is well-known for its digestive benefits, but it also plays a significant role in metabolism. It can help increase the metabolic rate, reduce bloating, and improve fat digestion. Ginger supports healthy circulation and enhances the body's ability to burn fat for energy. Dandelion Root Extract
Dandelion root is a natural diuretic and detoxifying herb. It helps the liver in processing waste and flushing out toxins. By reducing bloating and promoting better liver function, it can support the body's weight management process. Cayenne Pepper (Capsaicin)
Capsaicin, the compound that gives cayenne pepper its heat, has been shown to boost metabolism by increasing the body's calorie-burning capacity. It stimulates the thermogenesis process, promoting fat loss and improving digestive health.
Features of Hepato Burn?
Hepato Burn are a great way to lose weight quickly and safely. They contain a combination of natural ingredients that work together to suppress the appetite and boost metabolism.
This results in weight loss that is sustainable, as the pills promote satiety which means you feel full after eating smaller meals throughout the day.
While Hepato Burn capsules do have side effects, they're generally mild and short-lived. So, if you're looking for an easy and effective way to lose weight, these weight loss pills should be at the top of your list!
How Does Hepato Burn Work?
Hepato Burn works by targeting several crucial aspects of health, from boosting liver function to promoting fat loss. Here's how it helps: Enhances Liver Detoxification
A key function of Hepato Burn is to detoxify the liver, which plays a central role in metabolizing fats. The liver breaks down toxins and stores fat, so when it's functioning optimally, the body can process fat more efficiently. By supporting liver detoxification, Hepato Burn helps the body remove harmful substances and burn fat more effectively. Boosts Metabolism
Hepato Burn contains ingredients like green tea extract, cayenne pepper, and cinnamon that work synergistically to increase metabolic rate. This helps the body burn more calories, even at rest. The faster your metabolism, the more efficiently your body will convert food into energy and burn fat. Supports Healthy Fat Breakdown
The supplement's unique blend of herbs and spices helps your body break down fats more efficiently. Ingredients like ginger and turmeric enhance the digestive process, ensuring that fats are properly digested and absorbed, rather than stored in the body. Improves Insulin Sensitivity
Cinnamon and other ingredients in Hepato Burn help regulate blood sugar levels, which can improve insulin sensitivity. Insulin resistance is often linked to weight gain, so by improving how the body handles sugar, Hepato Burn supports healthy weight management. Increases Energy Levels
By improving liver health and metabolic function, Hepato Burn can help you feel more energetic throughout the day. The supplement helps the body convert food into energy more efficiently, reducing fatigue and improving overall stamina.
Order Now and Revitalize Your Health with Hepato Burn – Your Key to a Healthier Liver and Faster Fat Loss
Benefits of Hepato Burn
Hepato Burn offers a variety of health benefits that can positively impact your metabolism and weight management. Some of the key benefits include: Promotes Fat Loss : By supporting metabolism and enhancing fat breakdown, Hepato Burn can help individuals achieve their weight loss goals.
: By supporting metabolism and enhancing fat breakdown, Hepato Burn can help individuals achieve their weight loss goals. Supports Liver Health : The liver plays a crucial role in detoxification and fat metabolism, and Hepato Burn's ingredients help maintain healthy liver function.
: The liver plays a crucial role in detoxification and fat metabolism, and Hepato Burn's ingredients help maintain healthy liver function. Boosts Energy : Hepato Burn's ability to improve metabolic processes can help increase energy levels and combat fatigue.
: Hepato Burn's ability to improve metabolic processes can help increase energy levels and combat fatigue. Improves Digestion : Ingredients like ginger and cinnamon improve digestion and promote better nutrient absorption.
: Ingredients like ginger and cinnamon improve digestion and promote better nutrient absorption. Natural Detoxification: Hepato Burn aids in flushing out toxins from the liver and body, improving overall health.
Pros and Cons of Hepato Burn
Pros: Supports Liver Health:
Hepato Burn contains powerful ingredients like Milk Thistle and Turmeric Extract, which help support liver function by aiding detoxification and reducing inflammation. A healthy liver is essential for effective fat metabolism and overall body health. Boosts Metabolism:
The supplement features ingredients such as Green Tea Extract, Cayenne Pepper, and Cinnamon, known for their ability to naturally boost metabolism. This helps your body burn more calories, even at rest, aiding in weight loss. Promotes Fat Loss:
By enhancing fat metabolism and promoting fat breakdown, Hepato Burn aids in weight management. It helps the body use fat as a source of energy, making it easier to shed excess weight. Natural Detoxification:
Hepato Burn's ingredients, including Dandelion Root and Turmeric, work together to promote detoxification and eliminate toxins from the liver and body. This helps improve digestion and overall health. Increases Energy Levels:
With its ability to support metabolism and liver function, Hepato Burn can lead to more consistent energy throughout the day. This makes it a great supplement for individuals dealing with fatigue or sluggishness. Supports Digestion:
Ingredients like Ginger Root and Cinnamon work synergistically to improve digestion, reduce bloating, and promote better nutrient absorption. This can support overall gut health and aid in weight management. Natural Ingredients:
Hepato Burn is made from a blend of natural ingredients, making it a safer, more holistic option for those looking for liver support and metabolic enhancement without harsh chemicals or synthetic substances.
Cons: Possible Mild Side Effects:
While the ingredients are natural, some individuals may experience mild digestive upset, especially if they are sensitive to certain herbs like ginger or cinnamon. It's essential to monitor your body's reaction when starting the supplement. Results May Vary:
As with any supplement, the results can vary from person to person. Some individuals may experience faster results, while others may need to take the supplement for a longer period before noticing significant changes. Requires Consistent Use:
To see the best results, Hepato Burn needs to be taken consistently. Missing doses or using it intermittently may reduce its effectiveness in supporting metabolism and fat loss. Not Suitable for Everyone:
Hepato Burn may not be suitable for individuals with specific medical conditions or those who are pregnant, nursing, or taking certain medications. It's important to consult with a healthcare provider before starting any new supplement. Not a Quick Fix:
While Hepato Burn can enhance metabolism and support fat loss, it's not a magic pill. It should be paired with a healthy diet and exercise regimen for the best results in weight management and overall health. Limited Availability:
Hepato Burn is only available through select online retailers, which may make it difficult for some individuals to purchase. Buying from trusted sources is crucial to ensure the product's authenticity.
Who Should Take Hepato Burn?
Hepato Burn is suitable for individuals who: Are looking to support their liver function and improve metabolic health.
Struggle with weight management and need extra support in burning fat.
Want to boost energy levels and combat fatigue.
Are seeking a natural supplement to aid in detoxification and improve digestion.
How to Use Hepato Burn?
To get the most out of Hepato Burn, it's essential to follow the recommended dosage instructions. Most users take one or two capsules per day with meals. It's also important to stay hydrated and maintain a balanced diet to maximize the effects of the supplement.
Customer Reviews of Hepato Burn
Positive Feedback
Many users have reported favorable experiences with Hepato Burn, highlighting its effectiveness in supporting liver function and aiding weight management: Improved Energy Levels: Several customers have noted increased energy and reduced fatigue after incorporating Hepato Burn into their routine. One user mentioned feeling 'lighter, sharper, and more in control than I have in years' after consistent use.
Enhanced Digestion: Users have observed smoother digestion and reduced bloating. A customer shared, 'I felt less bloated, and my digestion just seemed smoother.'
Steady Weight Loss: Many individuals have experienced gradual weight loss, with some reporting a loss of up to 12 pounds in eight weeks.
Negative Feedback
While the majority of reviews are positive, some users have expressed concerns: Delayed Results : A few customers mentioned that the results were not immediate and required consistent use over several weeks.
: A few customers mentioned that the results were not immediate and required consistent use over several weeks. Mild Detox Symptoms: Some users experienced temporary fatigue or changes in digestion during the initial phase of use, which is common when the body is adjusting to a detoxifying supplement.
Possible Side Effects
Hepato Burn is made with natural ingredients, making it safe for most individuals. However, as with any supplement, it's always a good idea to consult with a healthcare professional before starting any new supplement, especially if you have existing medical conditions or are taking medication.
Some people may experience mild digestive upset or allergic reactions to certain ingredients, though these side effects are rare.
These supplements are designed to help you suppress your appetite, which in turn can help you lose weight.
However, there is little research on the long-term effects of figure weight loss pills. That said, some people do experience side effects. Before starting any kind of diet or supplement regimen, it's important to speak with a doctor.
Although figure weight loss pills are not regulated by the FDA, it's always best to be safe and avoid any potential side effects.
Hepato Burn Pricing
Hepato Burn is available in various package options to suit different needs and budgets. The pricing details are as follows:
Single Bottle (30-Day Supply)
Price: Approximately ₹2,000 – ₹2,500
Quantity: 60 capsules (2 capsules per day)
Two Bottles (60-Day Supply)
Price: Approximately ₹3,800 – ₹4,500
Quantity: 120 capsules
Three Bottles (90-Day Supply)
Price: Approximately ₹5,500 – ₹6,500
Quantity: 180 capsules
Six Bottles (180-Day Supply)
Price: Approximately ₹10,000 – ₹12,000
Quantity: 360 capsules
Where to Buy Hepato Burn
Hepato Burn is available through the Official Website and other trusted retailers. When purchasing, it's essential to ensure you are buying from a reputable source to guarantee the authenticity and quality of the product. Always look for discounts, bulk buying options, or money-back guarantees to get the best deal.
Order Now and Revitalize Your Health with Hepato Burn
Conclusion
Hepato Burn is a cutting-edge metabolism supplement that offers a natural and effective solution for supporting liver health, boosting metabolism, and aiding weight loss. With a carefully selected blend of ingredients, Hepato Burn provides a multi-faceted approach to improving overall health and wellness. Whether you're looking to detoxify your liver, burn fat more efficiently, or increase your energy levels, Hepato Burn may be the supplement to help you achieve your goals.
Email: [email protected]
Disclaimer: This article may contain affiliate links to the official HepatoBurn website or trusted third-party platforms. If you make a purchase through these links, we may earn a small commission at no additional cost to you. These earnings help support our site and allow us to provide reliable, research-backed content.
We only recommend products that we believe align with our mission and offer real value to our readers. However, individual results may vary, and we cannot guarantee specific outcomes or product quality beyond the manufacturer's claims.
The opinions expressed in this article are solely those of the author and independent of any affiliate partnerships. We encourage readers to conduct their own research before making any purchasing decisions.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/cb51ac85-cab3-40ef-b65a-d685ff85df83
https://www.globenewswire.com/NewsRoom/AttachmentNg/b94b63fd-50f8-4b83-8f47-514c95b8d8c5
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BonDo Seeks 100K USD Investments to Launch Innovative Brain Boosting Soup Brand by Year End
BonDo Seeks 100K USD Investments to Launch Innovative Brain Boosting Soup Brand by Year End

Yahoo

timean hour ago

  • Yahoo

BonDo Seeks 100K USD Investments to Launch Innovative Brain Boosting Soup Brand by Year End

BonDo, a part of Për Brand Solutions, is seeking funding to accelerate its healthy soup product to market at a commercial scale. Atlanta, Georgia, June 11, 2025 (GLOBE NEWSWIRE) -- BonDo BonDo, a pioneering nutrition startup founded by brain science researcher Era Kovanxhi, is officially opening the door to investment opportunities as it seeks to raise $100,000 to bring its innovative 'stir-in' soup product to market. Backed by years of academic research and inspired by Kovanxhi's personal health journey, BonDo is on a mission to make nutrient-dense meals accessible and functional, offering investors both profit and purpose. 'BonDo was born from my personal struggles as a student, balancing academic rigor with skin health, energy crashes, and a demanding schedule,' says Kovanxhi, a scientist currently pursuing a PhD in Brain Science and Education. 'I started experimenting with vitamin combinations to help my body and brain perform better. When I saw the difference in myself and my family, I knew I had something meaningful to share.' Created as a solution for busy individuals in need of fast, nutrient-rich meals, BonDo's stir-in soup flavor bits combine ease of use with cutting-edge nutrition. Simply add water for a complete, flavorful soup that supports brain health, energy, skin health, calcium retention, and anti-aging benefits. BodDo VarietiesWith varieties such as BonDo Butter Bits, BonDo Leftovers, and BonDo Soup Booster Bits, each Bit has unique combinations of flavorful nodes of herbs, garlic, lemon, avocado, etc. For the ones with a sweet tooth and love for caffeine, it offers BonDo Coffee Milk Variety Bits, BonDo Coffee Flavor Booster Bits, and BonDo Oatmeal, with flavorful nodes from coffee, almond, hazelnut, and apple crisps, to name a few. The BonDo Baby variety contains healthy nutrients of wheat berry, butternut, chamomile, avocado, pumpkin, and vegetables. Part of Për Brand Solutions, this research-based initiative was developed to merge science-driven wellness with community-focused accessibility. Each BonDo mix includes core ingredients like chia seeds, rice, or dairy, naturally rich in Omega 3, Vitamin D & E, and calcium, nutrients that aid in everything from bone strength to cognitive clarity. These nutrient combinations are also being explored in Kovanxhi's current work on Klotho protein, a molecule linked to anti-aging, calcium retention, and blood sugar regulation. BonDo - How To UseAlready tested through small-batch, homemade orders, BonDo is now ready to scale production with the help of aligned investors. The funding will go toward manufacturing, packaging, continuous product refinement, expansion of flavor options, marketing, brand development, and the launch of sales operations ahead of the 2025 holiday season. Investors will receive a percentage of profits, making this both a high-potential business venture and a socially driven opportunity. 'BonDo is more than food. It's a response to the overwhelming demand for convenience without compromising wellness,' says Kovanxhi. 'This is created for people like myself and my community, those low on time and budget, but who still deserve high-quality, nourishing meals.' Media Contact Name: Era Kovanxhi Email: There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any security or any other product or service in this article. Moreover, nothing contained in this should be construed as a recommendation to buy, sell, or hold any investment or security, or to engage in any investment strategy or transaction. It is your responsibility to determine whether any investment, investment strategy, security, or related transaction is appropriate for you based on your investment objectives, financial circumstances, and risk tolerance. Consult your business advisor, attorney, or tax advisor regarding your specific business, legal, or tax in to access your portfolio

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

Yahoo

time2 hours ago

  • Yahoo

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. 'It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon,' said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. Dr. Mazumdar is the founding Chief Executive Officer of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company. Prior to Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the precision medicine company's global partnership with Roche Pharmaceuticals. Earlier in her career, she held a position at Third Rock Ventures, where she focused on company formation and business development. She holds a B.S. in biological engineering from the Massachusetts Institute of Technology and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or follow us on Twitter. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection; the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; and the expectations regarding Relay Therapeutics' use of capital and expenses. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Relay Therapeutics' restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; the timing, execution, and expected impact of Relay Therapeutics' restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; the expected sufficiency of Relay Therapeutics' existing cash resources; the internal and external costs required for Relay Therapeutics' ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Relay Therapeutics' plans or both; the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade, or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact:Pete Rahmerprahmer@ Media:Dan Budwick1AB973-271-6085dan@

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

Yahoo

time2 hours ago

  • Yahoo

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 months Acceptable safety profile across all cohorts, including in cohort 8 with steeper step-up dosing Data support further dose optimization to maximize therapeutic benefit of MP0533, with dosing in cohort 9 now ongoing ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ('Molecular Partners' or the 'Company'), today announced a poster presentation with positive, updated data from a Phase 1/2a trial of the tetraspecific T-cell engager MP0533 in relapsed/refractory acute myeloid leukemia (AML), at the 30th EHA (European Hematology Association) Congress, taking place in Milan on June 12–15, 2025. The poster, Updated Results from the Ongoing Phase 1/2a Study of MP0533, a Tetra-Specific Designed Ankyrin Repeat Protein (DARPin; CD33 x CD123 x CD70 x CD3), in Patients with Relapsed/Refractory AML or MDS/AML, outlines the impact of accelerated step-up dosing regimen (steeper and faster) of MP0533 on exposure and clinical responses in cohort 8, providing the rationale for further optimization to the dosing regimen implemented in the ongoing cohort 9. Data from cohort 8 show that 3 of 8 evaluable patients (> 30%) achieved a clinical response after the first cycle, with one patient achieving a complete response and two patients a complete response with partial hematologic recovery as best overall response. Two patients maintained a response for more than 3 months and one patient remains on treatment, maintaining a response beyond 6 months at the time of data cutoff (14 April 2025). Cohort 8 implemented a higher starting dose than cohorts 1-7, and the inclusion of an additional day of dosing, reaching the target dose by day 12, as opposed to day 15 previously. Cohort 8 data indicate that patients maintained exposure to MP0533 for a longer period of time within the predicted therapeutic range through the accelerated step-up dosing scheme, within the first cycle. Data show that patients reached over 4 days of relevant exposure, with 5 out of 8 patients displaying > 50% blast reduction. MP0533 shows an acceptable safety profile after adjustment of the target dose in cohort 8. 'I am encouraged by the number and level of responses observed in the most recent cohort and have started to include patients with the new 'dense administration' schedule aiming to establish the full potential of this product for our R/R AML patients,' said Pierre Bories, MD, PhD, Principal Investigator at Institut Universitaire du Cancer Toulouse - Oncopole, France. In cohorts 1-7, where step-up dosing reached target dose by day 15, exposure to predicted therapeutic doses was limited to roughly 2 days in the first cycle, most likely due to target-mediated-drug deposition. This prior treatment protocol, despite demonstrating initial blast reductions in ~30% of patients, resulted in limited responses. Based on the encouraging antitumor activity observed in cohort 8, the amended protocol for cohort 9 and beyond includes further acceleration of the step-up dosing to reach therapeutically-relevant doses faster, increased frequency of dosing for higher cumulative MP0533 exposure, and the introduction of anti-CD20 premedication to mitigate loss of exposure, with the objective to further increase the depth and duration of responses in patients. Cohort 9 is currently dosing patients and initial data from the amended dosing scheme are expected in H2 2025. Additionally, future study cohorts will evaluate the combination of azacitidine/venetoclax with MP0533. Details of the presentation: Updated Results from the Ongoing Phase 1/2a Study of MP0533, a Tetra-SpecificDesigned Ankyrin Repeat Protein (DARPin; CD33 x CD123 x CD70 x CD3), in Patients withRelapsed/Refractory AML or MDS/AMLTime: June 13, 18:30 - 19:30 CEST (Poster Session 1) About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit and find us on LinkedIn and Twitter / X @MolecularPrtnrs For further details, please contact:Seth Lewis, SVP Investor Relations & StrategyConcord, Massachusetts, +1 781 420 2361 Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Tel: +41 44 575 19 35 Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024 offering. These statements may be identified by words such as 'aim', "anticipate', 'expect', 'guidance', 'intend', 'outlook', 'plan', 'potential', 'will' and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store